口服促性腺激素释放激素受体拮抗剂瑞卢戈利与亮丙瑞林相比减轻日本女性子宫内膜异位症相关疼痛:一项3期随机双盲非劣效性研究
这项在日本开展的3期多中心随机双盲双模拟活性对照研究,比较口服瑞卢戈利40 mg与皮下注射亮丙瑞林治疗子宫内膜异位症相关疼痛的疗效与安全性。主要终点为盆腔疼痛最大视觉模拟量表评分从基线至治疗结束前28天的变化,瑞卢戈利非劣效于亮丙瑞林,两者安全性相当,但瑞卢戈利组月经恢复更早。
要点
- 瑞卢戈利40 mg口服每日一次与亮丙瑞林皮下注射每4周一次均治疗24周。
- 最大视觉模拟量表评分变化:瑞卢戈利组-52.6±1.3,亮丙瑞林组-57.5±1.4。
- 两组发生率>10%的药物相关治疗中出现的不良事件包括潮热、子宫不规则出血、头痛和生殖道出血。
核心结论
- 瑞卢戈利在治疗子宫内膜异位症相关盆腔疼痛方面非劣效于亮丙瑞林。
- 两种药物的安全性特征相当,但瑞卢戈利组月经恢复更早,这对治疗后计划妊娠的女性是巨大获益。
研究设计与样本
- 3期、多中心、随机、双盲、双模拟、活性对照研究,在日本患者中开展。
- 研究对象为年龄≥20岁、月经周期规律(25-38天)、患有子宫内膜异位症或卵巢子宫内膜异位囊肿并报告盆腔疼痛的女性。
- 瑞卢戈利组口服瑞卢戈利40 mg每日一次,共24周;亮丙瑞林组皮下注射亮丙瑞林3.75 mg或1.88 mg每4周一次,共24周。
- 主要终点为盆腔疼痛最大视觉模拟量表评分从基线至治疗结束前28天的变化。
主要发现
- 最大视觉模拟量表评分变化:瑞卢戈利组-52.6±1.3,亮丙瑞林组-57.5±1.4。
- 卵巢子宫内膜异位囊肿缩小:瑞卢戈利组12.26±17.52 cm3,亮丙瑞林组14.10±18.81 cm3。
- 两组发生率均>10%的药物相关治疗中出现的不良事件为潮热、子宫不规则出血、头痛和生殖道出血。
- 因治疗中出现的不良事件而中止治疗的比例:瑞卢戈利组2.9%,亮丙瑞林组4.3%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of 40-mg relugolix (REL) compared with those of leuprorelin (LEU) in women with endometriosis-associated pain. DESIGN: Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study in Japanese patients. SETTING: Hospitals and clinics. PATIENT(S): Women aged ≥20 years with regular menstrual cycles (25-38 days) experiencing endometriosis or ovarian endometrioma and reporting pelvic pain. INTERVENTION(S): In the REL group, 40 mg of REL was orally administered once a day for 24 weeks. In the LEU group, 3.75 or 1.88 mg of LEU was subcutaneously injected every 4 weeks for 24 weeks. MAIN OUTCOME MEASURE(S): The primary endpoint was the change in the maximum visual analog scale score for pelvic pain from baseline until 28 days before the end of treatment. RESULT(S): Changes in the maximum visual analog scale score were -52.6 ± 1.3 for REL and -57.5 ± 1.4 for LEU. Ovarian endometrioma decreased by 12.26 ± 17.52 cm3 for REL and 14.10 ± 18.81 cm3 for LEU. Drug-related treatment emergent adverse events with an incidence of >10% for both groups were hot flush, metrorrhagia, headache, and genital hemorrhage. Discontinuations from treatment emergent adverse events were 2.9% for REL and 4.3% for LEU. CONCLUSION(S): Relugolix was noninferior to LEU for treating endometriosis-associated pelvic pain. Safety profiles of both medications were comparable, although menses returned earlier in patients taking REL, a huge benefit for women who plan to conceive after treatment. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT03931915.
引用
- Harada T, Osuga Y, Suzuki Y, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2021. PMID: 34895700. doi:10.1016/j.fertnstert.2021.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。